Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage

Nadège Bercovici, Agnès Heurtier, C. Vízler, Nathalie Pardigon, Christophe Cambouris, Pierre Desreumaux, Roland Liblau

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Insulin-dependent diabetes is an autoimmune disease targeting pancreatic β-islet cells. Recent data suggest that autoreactive CD8+ T cells are involved in both the early events leading to insulitis and the late destructive phase resulting in diabetes. Although therapeutic injection of protein and synthetic peptides corresponding to CD4+ T cell epitopes has been shown to prevent or block autoimmune disease in several models, down- regulation of an ongoing CD8+ T cell-mediated autoimmune response using this approach has not yet been reported. Using CL4-TCR single transgenic mice, in which most CD8+ T cells express a TCR specific for the influenza virus hemagglutinin HA512-520 peptide: K(d) complex, we first show that i.v. injection of soluble HA512-520 peptide induces transient activation followed by apoptosis of Tc1-like CD8+ T cells. We next tested a similar tolerance induction strategy in (CL4-TCR x Ins-HA)F1 double transgenic mice that also express HA in the β-islet cells and, as a result, spontaneously develop a juvenile onset and lethal diabetes. Soluble HA512-520 peptide treatment, at a time when pathogenic CD8+ T cells have already infiltrated the pancreas, very significantly prolongs survival of the double transgenic pups. In addition, we found that Ag administration eliminates CD8+ T cell infiltrates from the pancreas without histological evidence of bystander damage. Our data indicate that agonist peptide can down-regulate an autoimmune reaction mediated by CD8+ T cells in vivo and block disease progression. Thus, in addition to autoreactive CD4+ T cells, CD8+ T cells may constitute targets for Ag-specific therapy in autoimmune diseases.

Original languageEnglish
Pages (from-to)202-210
Number of pages9
JournalJournal of Immunology
Volume165
Issue number1
Publication statusPublished - Jul 1 2000

Fingerprint

Type 1 Diabetes Mellitus
Transgenic Mice
T-Lymphocytes
Peptides
Islets of Langerhans
Autoimmune Diseases
Pancreas
Down-Regulation
Injections
T-Lymphocyte Epitopes
Hemagglutinins
Orthomyxoviridae
Autoimmunity
Disease Progression
Therapeutics
Insulin
Apoptosis

ASJC Scopus subject areas

  • Immunology

Cite this

Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. / Bercovici, Nadège; Heurtier, Agnès; Vízler, C.; Pardigon, Nathalie; Cambouris, Christophe; Desreumaux, Pierre; Liblau, Roland.

In: Journal of Immunology, Vol. 165, No. 1, 01.07.2000, p. 202-210.

Research output: Contribution to journalArticle

Bercovici, Nadège ; Heurtier, Agnès ; Vízler, C. ; Pardigon, Nathalie ; Cambouris, Christophe ; Desreumaux, Pierre ; Liblau, Roland. / Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. In: Journal of Immunology. 2000 ; Vol. 165, No. 1. pp. 202-210.
@article{34fd95bf83a54b589540c26eca2a2ac7,
title = "Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage",
abstract = "Insulin-dependent diabetes is an autoimmune disease targeting pancreatic β-islet cells. Recent data suggest that autoreactive CD8+ T cells are involved in both the early events leading to insulitis and the late destructive phase resulting in diabetes. Although therapeutic injection of protein and synthetic peptides corresponding to CD4+ T cell epitopes has been shown to prevent or block autoimmune disease in several models, down- regulation of an ongoing CD8+ T cell-mediated autoimmune response using this approach has not yet been reported. Using CL4-TCR single transgenic mice, in which most CD8+ T cells express a TCR specific for the influenza virus hemagglutinin HA512-520 peptide: K(d) complex, we first show that i.v. injection of soluble HA512-520 peptide induces transient activation followed by apoptosis of Tc1-like CD8+ T cells. We next tested a similar tolerance induction strategy in (CL4-TCR x Ins-HA)F1 double transgenic mice that also express HA in the β-islet cells and, as a result, spontaneously develop a juvenile onset and lethal diabetes. Soluble HA512-520 peptide treatment, at a time when pathogenic CD8+ T cells have already infiltrated the pancreas, very significantly prolongs survival of the double transgenic pups. In addition, we found that Ag administration eliminates CD8+ T cell infiltrates from the pancreas without histological evidence of bystander damage. Our data indicate that agonist peptide can down-regulate an autoimmune reaction mediated by CD8+ T cells in vivo and block disease progression. Thus, in addition to autoreactive CD4+ T cells, CD8+ T cells may constitute targets for Ag-specific therapy in autoimmune diseases.",
author = "Nad{\`e}ge Bercovici and Agn{\`e}s Heurtier and C. V{\'i}zler and Nathalie Pardigon and Christophe Cambouris and Pierre Desreumaux and Roland Liblau",
year = "2000",
month = "7",
day = "1",
language = "English",
volume = "165",
pages = "202--210",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage

AU - Bercovici, Nadège

AU - Heurtier, Agnès

AU - Vízler, C.

AU - Pardigon, Nathalie

AU - Cambouris, Christophe

AU - Desreumaux, Pierre

AU - Liblau, Roland

PY - 2000/7/1

Y1 - 2000/7/1

N2 - Insulin-dependent diabetes is an autoimmune disease targeting pancreatic β-islet cells. Recent data suggest that autoreactive CD8+ T cells are involved in both the early events leading to insulitis and the late destructive phase resulting in diabetes. Although therapeutic injection of protein and synthetic peptides corresponding to CD4+ T cell epitopes has been shown to prevent or block autoimmune disease in several models, down- regulation of an ongoing CD8+ T cell-mediated autoimmune response using this approach has not yet been reported. Using CL4-TCR single transgenic mice, in which most CD8+ T cells express a TCR specific for the influenza virus hemagglutinin HA512-520 peptide: K(d) complex, we first show that i.v. injection of soluble HA512-520 peptide induces transient activation followed by apoptosis of Tc1-like CD8+ T cells. We next tested a similar tolerance induction strategy in (CL4-TCR x Ins-HA)F1 double transgenic mice that also express HA in the β-islet cells and, as a result, spontaneously develop a juvenile onset and lethal diabetes. Soluble HA512-520 peptide treatment, at a time when pathogenic CD8+ T cells have already infiltrated the pancreas, very significantly prolongs survival of the double transgenic pups. In addition, we found that Ag administration eliminates CD8+ T cell infiltrates from the pancreas without histological evidence of bystander damage. Our data indicate that agonist peptide can down-regulate an autoimmune reaction mediated by CD8+ T cells in vivo and block disease progression. Thus, in addition to autoreactive CD4+ T cells, CD8+ T cells may constitute targets for Ag-specific therapy in autoimmune diseases.

AB - Insulin-dependent diabetes is an autoimmune disease targeting pancreatic β-islet cells. Recent data suggest that autoreactive CD8+ T cells are involved in both the early events leading to insulitis and the late destructive phase resulting in diabetes. Although therapeutic injection of protein and synthetic peptides corresponding to CD4+ T cell epitopes has been shown to prevent or block autoimmune disease in several models, down- regulation of an ongoing CD8+ T cell-mediated autoimmune response using this approach has not yet been reported. Using CL4-TCR single transgenic mice, in which most CD8+ T cells express a TCR specific for the influenza virus hemagglutinin HA512-520 peptide: K(d) complex, we first show that i.v. injection of soluble HA512-520 peptide induces transient activation followed by apoptosis of Tc1-like CD8+ T cells. We next tested a similar tolerance induction strategy in (CL4-TCR x Ins-HA)F1 double transgenic mice that also express HA in the β-islet cells and, as a result, spontaneously develop a juvenile onset and lethal diabetes. Soluble HA512-520 peptide treatment, at a time when pathogenic CD8+ T cells have already infiltrated the pancreas, very significantly prolongs survival of the double transgenic pups. In addition, we found that Ag administration eliminates CD8+ T cell infiltrates from the pancreas without histological evidence of bystander damage. Our data indicate that agonist peptide can down-regulate an autoimmune reaction mediated by CD8+ T cells in vivo and block disease progression. Thus, in addition to autoreactive CD4+ T cells, CD8+ T cells may constitute targets for Ag-specific therapy in autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0034234485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234485&partnerID=8YFLogxK

M3 - Article

C2 - 10861053

AN - SCOPUS:0034234485

VL - 165

SP - 202

EP - 210

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -